SA Novavax vaccine trial shows efficacy against B.1.351 Covid-19 variant
Results from the University of the Witwatersrand Novavax coronavirus (Covid-19) vaccine trial show 51% efficacy against the B.1.351 variant in a South African study with HIV negative participants.
A group in the trial, which included people who are HIV positive, showed 43% efficacy.
Novavax is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes Covid-19 disease.
Professor of Vaccinology, co-author of the study, and the director of the Wits Vaccines & Infectious Diseases Analytics Research Unit Shabir Madhi led the Novavax Covid-19 vaccine trial in South Africa.
Publication of initial primary analysis showed cross-protection by the Novavax Covid-19 vaccine against the B.1.351 variant, making it the first published study to show protection against mild Covid-19 caused by the B.1.351 variant.
An updated analysis of the study indicated 100% protection against severe Covid-19 due to the B.1.351 variant.
“An efficacy of 50% is sufficient to meet the World Health Organization criteria for regulatory approval of the vaccine,” Madhi said.
The New England Journal of Medicine also published findings of the Phase 2b clinical trial conducted in South Africa on Wednesday.
Founder of Intercell USA, Inc. and president of research and development at Novavax Gregory M. Glenn says this data publication reinforces the encouraging safety profile and cross-protective effect across variants seen in studies of the vaccine to-date.
Comments
Research Reports
Projects
Latest News
Showroom
Our Easy Access Chute concept was developed to reduce the risks related to liner maintenance. Currently, replacing wear liners require that...
VISIT SHOWROOM
Education: Consulting with member companies to obtain the optimal benefits from their B-BBEE spending, skills resources as well as B-BBEE points
VISIT SHOWROOM
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation
